Table 3 The lifetime productivity (estimated by earnings) for patients with end stage kidney disease (ESKD) and their sex-, age-, and calendar year-matched referents, along with the relative loss of the index group

Male

 Aged 25–34

151,637 (123,093–163,971)

387,970 (386,059–388,912)

236,334 (222,645–263,113)

61% (57–68%)

 Aged 35–40

109,220 (93,881–114,167)

297,409 (296,215–298,148)

188,189 (182,892–202,950)

63% (61–69%)

 Aged 41–45

77,449 (70,523–79,523)

225,214 (224,683–225,945)

147,765 (145,748–154,131)

66% (65–69%)

 Aged 46–50

58,314 (55,265–59,676)

163,907 (163,176–164,086)

105,593 (103,698–108,174)

64% (63–66%)

 Aged 51–55

42,222 (40,145–43,191)

106,023 (105,570–106,268)

63,801 (62,555–65,445)

60% (59–62%)

 Aged 56–60

23,188 (22,310–23,882)

51,958 (51,721–52,201)

28,771 (27,954–29,622)

55% (54–57%)

 Aged 61–64

7,777 (7,468–8,110)

13,949 (13,784–14,144)

6,173 (5,829–6,425)

44% (41–47%)

Female

 Aged 25–34

120,035 (98,995–127,596)

311,230 (309,814–312,478)

191,195 (181,497–211,648)

61% (58–68%)

 Aged 35–40

107,202 (96,897–110,424)

230,081 (228,803–230,888)

122,879 (119,230–132538)

53% (52–58%)

 Aged 41–45

81,621 (76,597–84,070)

171,502 (170,676–172,250)

89,881 (87,120–94,302)

52% (51–55%)

 Aged 46–50

61,464 (57,861–62,758)

119,905 (119,329–120,319)

58,442 (56,722–61,452)

49% (47–51%)

 Aged 51–55

39,243 (37,521–40,410)

73,917 (73,491–74,242)

34,673 (33,449–36,263)

47% (45–49%)

 Aged 56–60

19,361 (18,786–19,971)

33,474 (33,256–33,711)

14,113 (13,334–14,641)

42% (40–44%)

 Aged 61–64

5,685 (5,457–5,901)

8,391 (8,293–8,519)

2,706 (2,441–2,865)

32% (29–35%)